Plain-English translation of NCT03858751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether medications from the LTM1201 family can help reduce obstructive sleep apnea—a condition where your throat muscles relax too much during sleep, blocking your airway. The study focuses on a specific problem: when people with sleep apnea fall asleep, the muscles that keep their airway open don't work as well as they should. Researchers want to see if this medication can strengthen those muscles and make breathing easier at night.
Current treatments for sleep apnea are limited and not ideal for everyone. This medication is designed to target the root cause—weak airway muscles during sleep—rather than just managing symptoms, potentially offering a new treatment option for people who can't use or don't respond well to existing therapies.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication or a placebo (inactive pill) to take before bed, and researchers would monitor how this affects your sleep apnea using sleep studies. The study involves spending nights in a sleep lab where your breathing and oxygen levels are carefully tracked. You'll be compared to other participants receiving different doses or a placebo to see which version works best and is safest.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States